Literature DB >> 15956567

An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies.

Birke Bartosch1, Géraldine Verney, Marlène Dreux, Peggy Donot, Yoann Morice, François Penin, Jean-Michel Pawlotsky, Dimitri Lavillette, Francois-Loïc Cosset.   

Abstract

Hepatitis C virus (HCV) circulates in the bloodstream in different forms, including complexes with immunoglobulins and/or lipoproteins. To address the significance of such associations, we produced or treated HCV pseudoparticles (HCVpp), a valid model of HCV cell entry and its inhibition, with naïve or patient-derived sera. We demonstrate that infection of hepatocarcinoma cells by HCVpp is increased more than 10-fold by human serum factors, of which high-density lipoprotein (HDL) is a major component. Infection enhancement requires scavenger receptor BI, a molecule known to mediate HDL uptake into cells as well as HCVpp entry, and involves conserved amino acid positions in hypervariable region 1 (HVR1) of the E2 glycoprotein. Additionally, we show that the interaction with human serum or HDL, but not with low-density lipoprotein, leads to the protection of HCVpp from neutralizing antibodies, including monoclonal antibodies and antibodies present in patient sera. Finally, the deletion or mutation of HVR1 in HCVpp abolishes infection enhancement and leads to increased sensitivity to neutralizing antibodies/sera compared to that of parental HCVpp. Altogether, these results assign to HVR1 new roles which are complementary in helping HCV to survive within its host. Besides immune escape by mutation, HRV1 can mediate the enhancement of cell entry and the protection of virions from neutralizing antibodies. By preserving a balance between these functions, HVR1 may be essential for the viral persistence of HCV.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15956567      PMCID: PMC1143705          DOI: 10.1128/JVI.79.13.8217-8229.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

Review 1.  Neutralization and antibody-dependent enhancement of dengue viruses.

Authors:  Scott B Halstead
Journal:  Adv Virus Res       Date:  2003       Impact factor: 9.937

2.  Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor.

Authors:  V Agnello; G Abel; M Elfahal; G B Knight; Q X Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

Review 3.  Virus entry, assembly, budding, and membrane rafts.

Authors:  Nathalie Chazal; Denis Gerlier
Journal:  Microbiol Mol Biol Rev       Date:  2003-06       Impact factor: 11.056

4.  Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor.

Authors:  Birke Bartosch; Alessandra Vitelli; Christelle Granier; Caroline Goujon; Jean Dubuisson; Simona Pascale; Elisa Scarselli; Riccardo Cortese; Alfredo Nicosia; François-Loïc Cosset
Journal:  J Biol Chem       Date:  2003-08-11       Impact factor: 5.157

5.  CD81 is required for hepatitis C virus glycoprotein-mediated viral infection.

Authors:  Jie Zhang; Glenn Randall; Adrian Higginbottom; Peter Monk; Charles M Rice; Jane A McKeating
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

Review 6.  Modulation of entry of enveloped viruses by cholesterol and sphingolipids (Review).

Authors:  Satinder S Rawat; Mathias Viard; Stephen A Gallo; Alan Rein; Robert Blumenthal; Anu Puri
Journal:  Mol Membr Biol       Date:  2003 Jul-Sep       Impact factor: 2.857

7.  Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles.

Authors:  Mayla Hsu; Jie Zhang; Mike Flint; Carine Logvinoff; Cecilia Cheng-Mayer; Charles M Rice; Jane A McKeating
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-21       Impact factor: 11.205

8.  In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes.

Authors:  Birke Bartosch; Jens Bukh; Jean-Christophe Meunier; Christelle Granier; Ronald E Engle; William C Blackwelder; Suzanne U Emerson; François-Loïc Cosset; Robert H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-14       Impact factor: 11.205

9.  Antibody-dependent enhancement of Ebola virus infection.

Authors:  Ayato Takada; Heinz Feldmann; Thomas G Ksiazek; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

Review 10.  SR-BI and cholesterol uptake into steroidogenic cells.

Authors:  Margery A Connelly; David L Williams
Journal:  Trends Endocrinol Metab       Date:  2003-12       Impact factor: 12.015

View more
  120 in total

1.  Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature.

Authors:  Michelle C Sabo; Vincent C Luca; Stuart C Ray; Jens Bukh; Daved H Fremont; Michael S Diamond
Journal:  Virology       Date:  2011-11-12       Impact factor: 3.616

Review 2.  Viral quasispecies evolution.

Authors:  Esteban Domingo; Julie Sheldon; Celia Perales
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

3.  The entire core protein of HCV JFH1 is required for efficient formation of infectious JFH1 pseudoparticles.

Authors:  Priyanka Shukla; Kristina N Faulk; Suzanne U Emerson
Journal:  J Med Virol       Date:  2010-05       Impact factor: 2.327

4.  A milestone for hepatitis C virus research: a virus generated in cell culture is fully viable in vivo.

Authors:  Jens Bukh; Robert H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-27       Impact factor: 11.205

5.  Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms.

Authors:  Rodrigo Velázquez-Moctezuma; Andrea Galli; Mansun Law; Jens Bukh; Jannick Prentoe
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

6.  Apolipoprotein c1 association with hepatitis C virus.

Authors:  Jean-Christophe Meunier; Rodney S Russell; Ronald E Engle; Kristina N Faulk; Robert H Purcell; Suzanne U Emerson
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

7.  Contribution of redox status to hepatitis C virus E2 envelope protein function and antigenicity.

Authors:  Emmanuel Fenouillet; Dimitri Lavillette; Silvia Loureiro; George Krashias; Guillemette Maurin; François-Loïc Cosset; Ian M Jones; Rym Barbouche
Journal:  J Biol Chem       Date:  2008-07-30       Impact factor: 5.157

8.  Hepatoma cell density promotes claudin-1 and scavenger receptor BI expression and hepatitis C virus internalization.

Authors:  Anne K Schwarz; Joe Grove; Ke Hu; Christopher J Mee; Peter Balfe; Jane A McKeating
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

Review 9.  Clinical impact of hepatitis B and C virus envelope glycoproteins.

Authors:  Hélène Jeulin; Aurélie Velay; John Murray; Evelyne Schvoerer
Journal:  World J Gastroenterol       Date:  2013-02-07       Impact factor: 5.742

Review 10.  Neutralizing antibodies in hepatitis C virus infection.

Authors:  Mirjam-B Zeisel; Samira Fafi-Kremer; Isabel Fofana; Heidi Barth; Francoise Stoll-Keller; Michel Doffoel; Thomas-F Baumert
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.